ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
임핀지(듀르발맙) 시장 규모는 향후 몇 년간 급속한 성장을 기록할 것으로 예상됩니다. 예측 기간 동안의 성장은 복합 요법의 사용 증가, 제약 R&D 증가, 암 발병률 증가, 면역 요법의 수용 확대, 규제 범위 확대, 의료 시설에 대한 투자 증가에 기인할 수 있습니다. 예측 기간 동안의 주요 동향으로는 맞춤형 의약품 기술의 채택, 맞춤형 의약품에 대한 집중, 바이오시밀러의 채택, 인공 지능 및 기계 학습의 통합, 제약 회사 간의 협력 등이 있습니다.
암의 이환율 증가가 임핀지(듀르발맙) 시장의 성장을 촉진할 것으로 예상됩니다. 암은 비정상적인 세포의 무제한 성장과 확산으로 특징지어지는 질병군으로, 고령화, 흡연, 불균형한 식습관, 비만 등이 암 발생률을 높이는 주요 요인으로 작용하고 있습니다. 임핀지(듀르발맙)은 면역 체계가 암 세포를 탐지하지 못하도록 방해하는 PD-L1 단백질을 억제하여 암을 치료하는 데 사용됩니다. 미국 국립암연구소(NIH)에 따르면, 2022년 미국 암 생존자 수는 1,810만 명으로, 2032년에는 2,250만 명으로 증가할 것으로 예상됩니다. 따라서 암 발병률의 증가는 시장에서 임핀지에 대한 수요를 촉진하고 있습니다.
맞춤형 의약품의 부상이 임핀지(듀르발맙) 시장의 성장을 촉진할 것으로 예상됩니다. 맞춤형 의약품은 유전적 구성, 생활 방식, 환경 등 개별 환자의 특성에 따라 치료법을 맞춤화하여 가장 효과적인 결과를 달성합니다. 유전학 기술, 분자 생물학, 정밀 진단 도구, 부작용을 최소화하면서 환자 결과를 개선하는 표적 치료법의 발전으로 맞춤형 치료에 대한 수요가 증가하고 있습니다. 임핀지는 PD-L1 단백질을 표적으로 함으로써 암 환자를 위한 맞춤형 면역 치료법을 가능하게 하고, 효능을 개선하며, 부작용을 줄임으로써 맞춤형 의약품에서 중요한 역할을 합니다. Personalized Medicine Coalition에 따르면, FDA는 2022년에 신약의 34%에 대해 맞춤형 의약품을 승인했으며, 이는 개별화된 치료에 대한 관심이 증가하고 있음을 강조합니다. 따라서 맞춤형 의약품의 부상은 임핀지 시장의 중요한 동력입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 바이오의약품 시장에서의 제품 특성
분자 유형
투여경로(ROA)
작용기전(MOA)
안전성과 유효성
제4장 시장 동향과 전략
제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제6장 세계의 성장 분석과 전략 분석 프레임워크
세계의 임핀지(듀르발맙) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 임핀지(듀르발맙) 시장 : 성장률 분석
세계의 임핀지(듀르발맙) 시장 실적 : 규모와 성장(2019-2024년)
세계의 임핀지(듀르발맙) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 임핀지(듀르발맙) : 전체 시장 규모(TAM)
제7장 세계 시장의 가격 분석과 예측
제8장 시장 세분화
세계의 임핀지(듀르발맙) 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
2.4mL 주사액
10mL 주사액
세계의 임핀지(듀르발맙) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 임핀지(듀르발맙) 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
국소 진행 요로 상피암
전이성 요로 상피암
기타 용도
제9장 임상적응증 세계 시장 역학
약제의 부작용
임상적응증의 발병률 및 유병률
제10장 지역별, 국가별 분석
세계의 임핀지(듀르발맙) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 임핀지(듀르발맙) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 경쟁 구도와 기업 프로파일
임핀지(듀르발맙) 시장 : 경쟁 구도
임핀지(듀르발맙) 시장 : 기업 프로파일
AstraZeneca PLC
제29장 세계 시장 : 파이프라인 분석
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 최근 시장 동향
제33장 시장의 잠재력이 높은 국가, 부문, 전략
임핀지(듀르발맙) 시장(2029년) : 새로운 기회를 제공하는 국가
임핀지(듀르발맙) 시장(2029년) : 새로운 기회를 제공하는 부문
임핀지(듀르발맙) 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제34장 부록
HBR
영문 목차
영문목차
Imfinzi (durvalumab) is a human monoclonal antibody and immunotherapy drug designed to block programmed death-ligand 1 (PD-L1), a protein that tumors use to evade immune system detection. It is used to treat various cancers, including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, and advanced urothelial carcinoma.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of imfinzi (durvalumab) include 2.4 mL injection and 10 mL injection. The 2.4 mL injection refers to a precise volume of the drug contained in a 2.4 milliliter vial or syringe, often used for accurate dosing during medical treatments. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies for applications such as locally advanced urothelial carcinoma, metastatic urothelial carcinoma, and other indications.
The imfinzi (durvalumab) market research report is one of a series of new reports from The Business Research Company that provides imfinzi (durvalumab) market statistics, including imfinzi (durvalumab) industry global market size, regional shares, competitors with imfinzi (durvalumab) market share, detailed imfinzi (durvalumab) market segments, market trends and opportunities, and any further data you may need to thrive in the imfinzi (durvalumab) industry. This Imfinzi (durvalumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The imfinzi (durvalumab) market size is expected to see parid growth in the next few years. It will grow to $4,143.4 million in 2029 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to growing use of combination therapies, increasing pharmaceutical R&D, rising prevalence of cancer, growing acceptance of immunotherapy, increasing regulatory footprint, and growing investment in healthcare facilities. Major trends in the forecast period include adoption of personalized medicine techniques, a focus on personalized medicine, adoption of biosimilars, integration of artificial intelligence and machine learning, and collaborations between pharmaceuticals.
The growing incidence of cancer is expected to drive the growth of the imfinzi (durvalumab) market. Cancer, a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, is becoming increasingly prevalent due to an aging population, smoking, poor diet, and obesity, all of which contribute to higher cancer rates. Durvalumab (Imfinzi) is used to treat cancer by inhibiting the PD-L1 protein, which prevents cancer cells from evading detection by the immune system. According to the National Cancer Institute (NIH), there were 18.1 million cancer survivors in the U.S. in 2022, with that number expected to rise to 22.5 million by 2032. The rising incidence of cancer is thus driving the demand for imfinzi in the market.
Rising personalized medicine is expected to propel the growth of the imfinzi (durvalumab) market. Personalized medicine tailors treatments based on individual patient characteristics such as genetic makeup, lifestyle, and environment to achieve the most effective outcomes. The demand for personalized treatments is growing due to advancements in genomic technologies, molecular biology, precision diagnostic tools, and targeted therapies that improve patient outcomes while minimizing side effects. Imfinzi, by targeting the PD-L1 protein, plays a critical role in personalized medicine by enabling tailored immunotherapy treatments for cancer patients, improving efficacy and reducing side effects. According to the Personalized Medicine Coalition, the FDA approved personalized medicines for 34% of new drugs in 2022, emphasizing the increasing focus on individualized therapies. Therefore, the rise in personalized medicine is a significant driver for the imfinzi market.
A key trend in the imfinzi (durvalumab) market is the focus on gaining regulatory approvals to expand its use for additional cancer types, enhance clinical indications, and broaden its market reach. Regulatory approvals from authorities like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) allow for the marketing and use of drugs in specific regions. For example, in September 2022, AstraZeneca received FDA approval for durvalumab (Imfinzi) to treat locally advanced or metastatic biliary tract cancer (BTC) in adults. This approval was based on the results of the TOPAZ-1 trial, which showed that durvalumab combined with gemcitabine and cisplatin significantly improved overall survival and progression-free survival in patients with BTC. The success of such trials and regulatory approvals is expected to increase the market reach of Imfinzi, further driving its growth.
Key player operating in the imfinzi (durvalumab) market is AstraZeneca PLC.
North America was the largest region in the imfinzi (durvalumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in imfinzi (durvalumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the imfinzi (durvalumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The imfinzi (durvalumab) market consists of sales of products including Keytruda, Opdivo, Tecentriq, Libtayo, Bavencio and Emerging PD-1/PD-L1 Inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Imfinzi (durvalumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on imfinzi (durvalumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for imfinzi (durvalumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The imfinzi (durvalumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: 2.4mL Injection; 10mL Injection
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Imfinzi (durvalumab) Market Characteristics
3. Imfinzi (durvalumab) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Imfinzi (durvalumab) Market Trends And Strategies
5. Imfinzi (durvalumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global Imfinzi (durvalumab) Growth Analysis And Strategic Analysis Framework
6.1. Global Imfinzi (durvalumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Imfinzi (durvalumab) Market Growth Rate Analysis
6.4. Global Imfinzi (durvalumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Imfinzi (durvalumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Imfinzi (durvalumab) Total Addressable Market (TAM)
7. Global Imfinzi (durvalumab) Market Pricing Analysis & Forecasts
8. Imfinzi (durvalumab) Market Segmentation
8.1. Global Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
2.4mL Injection
10mL Injection
8.2. Global Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
8.3. Global Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Other Applications
9. Global Imfinzi (durvalumab) Market Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Imfinzi (durvalumab) Market Regional And Country Analysis
10.1. Global Imfinzi (durvalumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Imfinzi (durvalumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
